These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10446007)

  • 1. A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis.
    Veras P; Brodskyn C; Balestieri F; Freitas Ld; Ramos A; Queiroz A; Barral A; Beverley S; Barral-Netto M
    Mem Inst Oswaldo Cruz; 1999; 94(4):491-6. PubMed ID: 10446007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.
    Streit JA; Recker TJ; Filho FG; Beverley SM; Wilson ME
    J Immunol; 2001 Feb; 166(3):1921-9. PubMed ID: 11160240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a safe live Leishmania vaccine line by gene replacement.
    Titus RG; Gueiros-Filho FJ; de Freitas LA; Beverley SM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10267-71. PubMed ID: 7479765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
    Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
    Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
    Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
    Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.
    Campbell K; Diao H; Ji J; Soong L
    Infect Immun; 2003 Nov; 71(11):6270-8. PubMed ID: 14573646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.
    Pratti JE; Ramos TD; Pereira JC; da Fonseca-Martins AM; Maciel-Oliveira D; Oliveira-Silva G; de Mello MF; Chaves SP; Gomes DC; Diaz BL; Rossi-Bergmann B; de Matos Guedes HL
    Parasit Vectors; 2016 Oct; 9(1):534. PubMed ID: 27716449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.
    Perez Brandan C; Padilla AM; Xu D; Tarleton RL; Basombrio MA
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1418. PubMed ID: 22180798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
    Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
    J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A; Jaafari MR; Khamesipour A
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
    Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
    Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.